Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis
Year: 2026
Type: article
Study design: Clinical Trial
Source: New England Journal of Medicine
Authors: Jonathan Barratt, Robert M. Brenner, Sean J. Barbour, Kirk N. Campbell, Tom Doan, Necmi Eren, Jürgen Floege, Marshall W. Fordyce, Vivekanand Jha, Zeeshan Khawaja, Beom Seok Kim, Adrian Liew, Bart Maes, Atanu Pal, Roberto Pecoits-Filho, Richard K.S. Phoon, Dana V. Rizk, Hitoshi Suzuki, Vladimír Tesař, Hernán Trimarchi, Xuelian Wei, Lixi Yu, Hong Zhang, Richard Lafayette
Institutions: University of Leicester, University of British Columbia, University of Pennsylvania, Kocaeli Üniversitesi, Universitätsklinikum Aachen, Manipal Academy of Higher Education, Imperial College London, Yonsei University, Mount Elizabeth Novena Hospital, AZ Delta, Institute of Post Graduate Medical Education and Research, Pontifícia Universidade Católica do Paraná, Arbor Research Collaborative for Health, The University of Sydney, Westmead Hospital, University of Alabama at Birmingham, Juntendo University Urayasu Hospital, Charles University, Hospital Británico de Buenos Aires, Peking University First Hospital, Stanford University
Language: English
Subfield: Nephrology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7223203179